Skip to main content
Log in

Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders

  • Metabolomics
  • Published:
Journal of Inherited Metabolic Disease

Abstract

Tandem mass spectrometry (MS/MS) is a highly sensitive and specific technique. Thanks to the development of triple quadrupole analyzers, it is becoming more widely used in laboratories working in the field of inborn errors of metabolism. We review here the state of the art of this technique applied to the diagnosis of lysosomal storage disorders (LSDs) and how MS/MS has changed the diagnostic rationale in recent years. This fine technology brings more sensitive, specific, and reliable methods than the previous biochemical ones for the analysis of urinary glycosaminoglycans, oligosaccharides, and sialic acid. In sphingolipidoses, the quantification of urinary sphingolipids (globotriaosylceramide, sulfatides) is possible. The measurement of new plasmatic biomarkers such as oxysterols, bile acids, and lysosphingolipids allows the screening of many sphingolipidoses and related disorders (Niemann–Pick type C), replacing tedious biochemical techniques. Applied to amniotic fluid, a more reliable prenatal diagnosis or screening of LSDs is now available for fetuses presenting with antenatal manifestations. Applied to enzyme measurements, it allows high throughput assays for the screening of large populations, even newborn screening. The advent of this new method can modify the diagnostic rationale behind LSDs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Abbreviations

AF:

Amniotic fluid

ARSA:

Arylsulfatase A

BAB:

Butyl-4-aminobenzoate

CLN:

Ceroid lipofuscinosis

CS:

Chondroitin sulfate

DBS:

Dried blood spots

DMB:

1,9-Dimethylmethylene blue

DUS:

Dried urine spots

DS:

Dermatan sulfate

ERT:

Enzyme replacement therapy

FD:

Fabry disease

FIA:

Flow injection analysis

GAGs:

Glycosaminoglycans

Gb3 :

Globotriaosylceramide

GD:

Gaucher disease

GlcNAsn:

Aspartylglucosamine

GSD:

Glycogen storage disease

GVUS:

Genetic variant of unknown significance

HS:

Heparan sulfate

IS:

Internal standard

ISSD:

Infantile sialic acid storage disorder

KD:

Krabbe disease

KS:

Keratan sulfate

LALD:

Lysosomal acid lipase deficiency

LC:

Liquid chromatography

LLE:

Liquid–liquid extraction

LSDs:

Lysosomal storage disorders

LSL:

Lysosphingolipid

LysoGalCer:

Lysogalactosylceramide

Lyso-Gb3 :

Lysoglobotriaosylceramide

LysoGlcCer:

Lysoglucosylceramide

LysoHexCer:

Lysohexosylceramide

LysoSM:

Lysosphingomyelin

Lyso509:

Analogue 509 of lysosphingomyelin

MLD:

Metachromatic leukodystrophy

MPS:

Mucopolysaccharidosis

MRM:

Multiple reaction monitoring

MoM:

Multiple of median

MS/MS:

Tandem mass spectrometry

MSD:

Multiple sulfatase deficiency

NBS:

Newborn screening

NIHF:

Nonimmune hydrops fetalis

NP:

Niemann–Pick disease

NPAB:

Niemann-Pick disease type A/B

NPC:

Niemann–Pick disease type C

OS:

Oligosaccharides

PD:

Pompe disease

PMP:

1-Phenyl-3-methyl-5-pyrazolone

RT:

Retention time

SL:

Sphingolipid

SM:

Sphingomyelin

SPE:

Solid-phase extraction

TLC:

Thin-layer chromatography

TOF:

Time of flight

References

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Monique Piraud.

Ethics declarations

Conflict of interest

David Cheillan and Séverine Ruet declare they have no conflict of interest.

Christiane Auray-Blais declares she has received reimbursement for attending a symposium from Shire and Sanofi-Genzyme, fees for speaking or organizing education from Shire and Sanofi-Genzyme, funds for research or for a member of staff from Shire, Sanofi-Genzyme and BioMarin Pharmaceuticals, fees for consulting from Amicus Therapeutics, funds for traveling expenses and lectures given from Waters Corp.

Roseline Froissart declares she has received reimbursement for attending a symposium from Sanofi-Genzyme.

Pamela Lavoie declares she has received reimbursement for attending a symposium from Sanofi-Genzyme, BioMarin Pharmaceuticals and Waters Corp, fees for speaking or organizing education from Shire.

Philippe Latour and Cécile Pagan declare they have received reimbursement for attending a symposium and fees for speaking or organizing education from Actelion Pharmaceuticals.

Magali Pettazzoni declares she has received reimbursement for attending a symposium from Shire and BioMarin Pharmaceuticals.

Monique Piraud declares she has received reimbursement for attending a symposium from Shire, Sanofi-Genzyme, and Actelion Pharmaceuticals.

Christine Vianey-Saban declares she has received reimbursement for attending a symposium from Sanofi-Genzyme and BioMarin Pharmaceuticals, and funds for research or for a member of staff from Sanofi-Genzyme.

Additional information

Responsible Editor: Ron A Wevers

Electronic supplementary material

ESM 1

(DOC 195 kb)

ESM 1

(DOC 130 kb)

ESM 2

(DOC 264 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Piraud, M., Pettazzoni, M., Lavoie, P. et al. Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders. J Inherit Metab Dis 41, 457–477 (2018). https://doi.org/10.1007/s10545-017-0126-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10545-017-0126-3

Keywords

Navigation